# Lux Capital

Source: https://onco.cc/companies/lux-capital/  
OnCo record `lux-capital` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A New York venture firm that backs deep technology companies, from defence and AI to biology. Its biotech holdings include the AI drug discovery company Recursion and the imaging-based drug hunter Eikon Therapeutics.

## Summary

Lux Capital was founded in 2000 by Peter Hebert, Robert Paull and Josh Wolfe and is based in New York (Wikipedia). Its tagline is 'We turn sci-fi into sci-fact' and its companies page mixes defence (Anduril), AI (Hugging Face, Cognition) and space with life sciences. Biology-related holdings on the companies page are Recursion Pharma (high-throughput biology and machine learning for drug discovery, which runs oncology programmes), Eikon Therapeutics (single-molecule live-cell imaging for drug discovery), Kallyope (gut-brain axis), eGenesis (gene-edited organs) and Benchling (R&D software). Lux is a generalist rather than an oncology specialist, and its page does not describe disease areas, so its relevance to cancer is indirect.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: vc
- HQ: New York, NY
- Type: investor
- Website: https://www.luxcapital.com/

## Notes

- No company on the fetched Lux pages is described as oncology-focused; Recursion and Eikon are cited as drug discovery platforms with cancer programmes known from elsewhere.

## Sources

- Official website: https://www.luxcapital.com/
- Companies: https://www.luxcapital.com/companies
- Wikipedia: https://en.wikipedia.org/wiki/Lux_Capital

## Connected records

- companies: [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/), [Trial Library](https://onco.cc/companies/trial-library/)

---
JSON: https://onco.cc/api/v1/entities/lux-capital.json